EpiCast Report: Bladder Cancer - Epidemiology Forecast to 2022

Reportstack has announced a new market report on EpiCast Report: Bladder Cancer - Epidemiology Forecast to 2022. With more than 12 million new cases occurring worldwide each year, bladder cancer is estimated to be the ninth most common cancer, and the thirteenth most numerous cause of death from cancer (Parkin, 2008; Ploeg et al., 2009). The major risk factors for bladder cancer are exposure to smoking and occupational risk factors such as exposure to aromatic amines. These risk factors are more prevalent among men, which makes the disease the seventh most common cancer in men, whereas it is the seventeenth most common cancer in women (Ploeg et al., 2009). The majority of bladder cancer cases are among older individuals with the median age at diagnosis being 73 years; because of this, the comorbidities associated with bladder cancer are similar to conditions typically occurring in older age and therefore, are not specific to bladder cancer (Prout et al., 2005). 

By 2022, epidemiologists forecast that the 6MM are expected to have 199,691 incident cases of bladder cancer, representing a 22.2% increase from the number of incident cases in 2012 (163,380 incident cases). In 2012, the 6MM had 575,251 five-year prevalent cases of bladder cancer and epidemiologists forecast that by 2022, this number will grow to 703,227 five-year prevalent cases at an Annual Growth Rate (AGR) of 2.22%.

This forecast is supported by at least 10 years of historical data obtained from country-specific studies published by the World Health Organization’s (WHO) International Agency for Research on Cancer (IARC), the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) Program, and the European Cancer Registry’s fourth database registry (EUROCARE-4). The IARC’s Cancer Incidence in Five Continents (CI-5) Plus data are the gold standard for country-level comparative analysis and was used to provide detailed case segmentation for each country by age and sex. Another major strength of this analysis is that epidemiologists were able to forecast incident cases of bladder cancer in the 6MM by age, sex, and stage at diagnosis. Furthermore, the forecast methodology was also consistent across all markets, thereby allowing for a meaningful global comparison.

Scope
The Bladder Cancer EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of bladder cancer in the 6MM (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast for the incident cases of bladder cancer segmented by sex, age (in five-year age groups beginning at 15 years and ending at 75 years and older), and cancer stage at diagnosis (in situ, local, regional, distant, and unstaged), in addition to five-year prevalent cases in these markets.
The bladder cancer epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons To Buy
Develop business strategies by understanding the trends shaping and driving the global bladder cancer market.
Quantify patient populations in the global bladder cancer market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for bladder cancer therapeutics in each of the markets covered.

To view the table of contents and know more details please visit EpiCast Report: Bladder Cancer - Epidemiology Forecast to 2022 report.